Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer
NCT05034133Phase 2Unknown
- Sponsor
- Beijing Haidian Hospital
- Start
- Sep 2021
- Primary completion
- Aug 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in small cell lung cancer (SCLC), sponsored by Beijing Haidian Hospital. Status: unknown.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05034133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05034133.